Gilead’s oral ulcerative colitis drug shows significant remission in Phase 2 trial
read at STAT ↗Positive readoutPositive
Gilead Sciences reported results from a Phase 2 trial of its oral ulcerative colitis drug emvistegrast.
In the study, patients took a 200 mg daily dose for 12 weeks and achieved a 23% placebo-adjusted clinical remission rate, a statistically significant improvement.
The outcome exceeded analyst expectations and could bolster Gilead’s pipeline in inflammatory and autoimmune diseases.
source
This writeup was produced by pharmadog from original reporting by STAT.
Original headline: “STAT+: Gilead’s IBS drug eliminated symptoms for patients, mid-stage study finds”
read at STAT ↗553 words · retrieved 1h ago
comments(0)
5-min edit window · permanent after that